Cellectis Zukünftiges Wachstum

ENXTPA:ALCLS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	140	-40	-63	N/A	3
12/31/2025	64	-68	-95	N/A	5
12/31/2024	30	-43	-74	N/A	6
3/31/2024	12	-78	-21	-20	N/A
12/31/2023	9	-109	-26	-25	N/A
9/30/2023	25	-72	-67	-66	N/A
6/30/2023	25	-77	-76	-75	N/A
3/31/2023	25	-91	-81	-79	N/A
12/31/2022	26	-91	-90	-87	N/A
9/30/2022	-5	-63	-109	-107	N/A
6/30/2022	4	-78	-118	-112	N/A
3/31/2022	14	-99	-111	-100	N/A
12/31/2021	39	-86	-123	-105	N/A
9/30/2021	68	-129	-154	-117	N/A
6/30/2021	67	-121	-151	-113	N/A
3/31/2021	59	-113	-169	-123	N/A
12/31/2020	60	-37	-125	-80	N/A
9/30/2020	73	-79	-80	-49	N/A
6/30/2020	73	-66	-76	-46	N/A
3/31/2020	71	-67	-64	-45	N/A
12/31/2019	23	-102	-82	-69	N/A
9/30/2019	20	-88	-100	-87	N/A
6/30/2019	11	-95	-88	-79	N/A
3/31/2019	17	-69	-77	-71	N/A
12/31/2018	21	-79	-73	-68	N/A
9/30/2018	25	-83	-60	-57	N/A
6/30/2018	31	-86	-60	-58	N/A
3/31/2018	31	-105	-59	-56	N/A
12/31/2017	34	-99	N/A	-52	N/A
9/30/2017	40	-86	N/A	-41	N/A
6/30/2017	45	-74	N/A	N/A	N/A
3/31/2017	57	-56	N/A	-28	N/A
12/31/2016	56	-67	N/A	-33	N/A
9/30/2016	76	-45	N/A	-6	N/A
6/30/2016	74	-45	N/A	N/A	N/A
3/31/2016	65	-64	N/A	-17	N/A
12/31/2015	63	-23	N/A	4	N/A
9/30/2015	39	-28	N/A	2	N/A
6/30/2015	37	-10	N/A	34	N/A
3/31/2015	33	12	N/A	47	N/A
12/31/2014	32	3	N/A	51	N/A
9/30/2014	28	-8	N/A	18	N/A
6/30/2014	24	-21	N/A	-18	N/A
3/31/2014	21	-29	N/A	-22	N/A
12/31/2013	18	-36	N/A	-26	N/A
9/30/2013	15	-33	N/A	-29	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALCLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ALCLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ALCLS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ALCLSDie Einnahmen des Unternehmens (39.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.8% pro Jahr).

Hohe Wachstumseinnahmen: ALCLSDie Einnahmen des Unternehmens (39.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ALCLS in 3 Jahren voraussichtlich hoch sein wird

Cellectis Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 29%

Price target decreased to €20.50

Consensus EPS estimates increase to -US$2.44

Consensus forecasts updated

Recent updates

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

Cellectis Announces Chief Financial Officer Changes

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

New major risk - Financial position

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

New major risk - Share price stability

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.99 loss per share (vs US$2.55 loss in FY 2021)

Now 20% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Now 35% undervalued

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Now 22% undervalued

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Consensus revenue estimates fall by 29%

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Price target decreased to €20.50